Dexmedetomidine attenuates lipopolysaccharide-induced renal cell fibrotic phenotypic changes by inhibiting necroinflammation via activating α < sub > 2 < /sub > -adrenoceptor: A combined randomised animal and in vitro study

CONCLUSIONS: Dex reduced EMT following LPS stimulation whilst simultaneously inhibiting pyroptosis and necroptosis via α2-AR activation in the renal tubular cells. The "anti-fibrotic" and cytoprotective properties and its clinical use of Dex need to be further studied.PMID:38513598 | DOI:10.1016/j.biopha.2024.116462

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 21, 2024 Category: Drugs & Pharmacology Authors: Qizhe Sun Priyanka Kamath Yibing Sun Min Liang Lingzhi Wu Enqiang Chang Qian Chen Azeem Alam Yi Liu Hailin Zhao Daqing Ma Source Type: research